• Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
Search
Arvinas Logo
Arvinas logo
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
Search
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
  • Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
09DecDecember 9, 2025

Circulating Tumor DNA Biomarker Analyses of a Phase 1/2 Study Evaluating Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in ER+/HER2- Advanced Breast Cancer

09DecDecember 9, 2025

Real-world Prevalence of ESR1 Mutations Among Patients With ER+/HER2- Metastatic Breast Cancer After First-line Treatment With Endocrine Therapy and/or a CDK4/6 Inhibitor

09DecDecember 9, 2025

Subgroup Analyses of VERITAC-2: A Phase 3 Trial of Vepdegestrant, a PROTAC ER Degrader, vs Fulvestrant in ER+/HER2- Advanced Breast Cancer

06DecDecember 6, 2025

ARV-393, a PROTAC BCL6 Degrader, Combined With the CD20×CD3 Bispecific Glofitamab in a Preclinical Model of HGBCL

15NovNovember 15, 2025

ARV-102, a PROTAC LRRK2 Degrader, Modulates Pathways Associated With Parkinson’s Disease and Progressive Supranuclear Palsy: Proteomic Analyses of CSF From Non-human Primates and Healthy Volunteers

09NovNovember 9, 2025

Development of a Discrete Choice Experiment Survey to Assess Patient Preferences for Treatment of Metastatic Breast Cancer

09NovNovember 9, 2025

Real-World Burden of Illness in Patients With ER+/HER2- ABC Receiving Second-Line Treatment: Interim Results of Longitudinal Health Utility Data

05NovNovember 5, 2025

Preclinical Antitumor Activity of Potent and Orally Bioavailable PROTAC HPK1 Degraders as Monotherapy or Combined With an Anti-PD-1 Antibody

22OctOctober 22, 2025

Vepdegestrant, a PROTAC ER Degrader, Induces Greater ER Degradation and Antitumor Activity Relative to SERDs in Preclinical ER+ Breast Cancer Models

22OctOctober 22, 2025

Preclinical Activity of ARV-806, a PROTAC KRAS G12D Degrader

123Next  
Arvinas logo
  • Careers
  • Privacy Policy
  • Terms of Use
LinkedIn
X

Accessibility Statement

© 2026 Arvinas. All rights reserved.

Arvinas

You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

GO BACK
CONTINUE